Human Genome Epidemiology Literature Finder
Records 1 - 13 (of 13 Records) |
Query Trace: Diarrhea and CYP3A4[original query] |
---|
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer chemotherapy and pharmacology 2008 Aug 62 (3): 529-37. Sai Kimie, Saito Yoshiro, Fukushima-Uesaka Hiromi, Kurose Koichi, Kaniwa Nahoko, Kamatani Naoyuki, Shirao Kuniaki, Yamamoto Noboru, Hamaguchi Tetsuya, Kunitoh Hideo, Ohe Yuichiro, Tamura Tomohide, Yamada Yasuhide, Minami Hironobu, Ohtsu Atsushi, Yoshida Teruhiko, Saijo Nagahiro, Sawada Jun-ic |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Mar 26 (7): 1119-27. Rudin Charles M, Liu Wanqing, Desai Apurva, Karrison Theodore, Jiang Xuemin, Janisch Linda, Das Soma, Ramirez Jacqueline, Poonkuzhali Balasubramanian, Schuetz Erin, Fackenthal Donna Lee, Chen Peixian, Armstrong Deborah K, Brahmer Julie R, Fleming Gini F, Vokes Everett E, Carducci Michael A, Ratain Mark |
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jun 16 (11): 3078-87. Lind Joline S W, Dingemans Anne-Marie C, Groen Harry J M, Thunnissen Frederik B, Bekers Otto, Heideman Daniëlle A M, Honeywell Richard J, Giovannetti Elisa, Peters Godefridus J, Postmus Pieter E, van Suylen Robert Jan, Smit Egbert |
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jan 16 (2): 736-42. van der Bol Jessica M, Mathijssen Ron H J, Creemers Geert-Jan M, Planting André S Th, Loos Walter J, Wiemer Erik A C, Friberg Lena E, Verweij Jaap, Sparreboom Alex, de Jong Floris |
Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer 2015 Jul 16 (4): 274-81. Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masato |
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2016 Mar 93 69-76. Hirose Takashi, Fujita Ken-Ichi, Kusumoto Sojiro, Oki Yasunari, Murata Yasunori, Sugiyama Tomohide, Ishida Hiroo, Shirai Takao, Nakashima Masanao, Yamaoka Toshimitsu, Okuda Kentaro, Ohmori Tohru, Sasaki Yasutsu |
Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer chemotherapy and pharmacology 2019 Aug . Reddick Samuel J, Campagne Olivia, Huang Jie, Onar-Thomas Arzu, Broniscer Alberto, Gajjar Amar, Stewart Clinton |
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. Therapeutic advances in medical oncology 2019 6 11 1758835919846421. Bruera Gemma, Massacese Silvia, Pepe Francesco, Malapelle Umberto, Dal Mas Antonella, Ciacco Eugenio, Calvisi Giuseppe, Troncone Giancarlo, Simmaco Maurizio, Ricevuto Enri |
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K? inhibitor therapy. Blood 2020 12 137 (20): 2817-2826. Mato Anthony R, Ghosh Nilanjan, Schuster Stephen J, Lamanna Nicole, Pagel John M, Flinn Ian W, Barrientos Jacqueline C, Rai Kanti R, Reeves James A, Cheson Bruce D, Barr Paul M, Kambhampati Suman, Lansigan Frederick, Pu Jeffrey J, Skarbnik Alan P, Roeker Lindsey, Fonseca Gustavo A, Sitlinger Andrea, Hamadeh Issam S, Dorsey Colleen, LaRatta Nicole, Weissbrot Hanna, Luning Prak Eline T, Tsao Patricia, Paskalis Dana, Sportelli Peter, Miskin Hari P, Weiss Michael S, Svoboda Jakub, Brander Danielle |
Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients. Pharmacogenomics and personalized medicine 2021 14 1463-1474. Cheng Fang, Li Qiang, Wang Jinglin, Hu Min, Zeng Fang, Wang Zhendi, Zhang |
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. Investigational new drugs 2022 9 40 (6): 1254-1262. Yokota Hayato, Sato Kazuhiro, Sakamoto Sho, Okuda Yuji, Fukuda Natsuki, Asano Mariko, Takeda Masahide, Nakayama Katsutoshi, Miura Masato |
Importance of Pharmacogenetics and Drug-Drug Interactions in a Kidney Transplanted Patient. Life (Basel, Switzerland) 2023 8 13 (8): . Julia Concha, Estela Sangüesa, Ana M Saez-Benito, Ignacio Aznar, Nuria Berenguer, Loreto Saez-Benito, M Pilar Ribate, Cristina B Garc |
Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer. International journal of molecular sciences 2023 3 24 (6): . Cantara Silvia, Dalmiglio Cristina, Marzocchi Carlotta, Sagnella Alfonso, Brilli Lucia, Trimarchi Andrea, Maino Fabio, Valerio Laura, Castagna Maria Graz |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: